APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGF Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global VEGF Antibody Market Outlook and Growth Opportunities 2026

31 December 2025214 pages

Choose your research edition.

Industry ResearchVEGF Antibody Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Antibody Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal VEGF Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Antibody Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Antibody Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global VEGF Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the VEGF Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the VEGF Antibody market include Abcam, Abnova, Absolute Antibody, Agrisera, BioLegend, Bio-Rad, Bon Opus Biosciences, Creative Biomart and Enzo Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global VEGF Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VEGF Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VEGF Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the VEGF Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

VEGF Antibody Segment by Company

Abcam

Abnova

Absolute Antibody

Agrisera

BioLegend

Bio-Rad

Bon Opus Biosciences

Creative Biomart

Enzo Life Sciences

ImmunoStar

LifeSpan Biosciences

MilliporeSigma

Novus Biologicals

OriGene

ProMab

R&D Systems

Rockland Immunochemicals

Santa Cruz Biotechnology

Sino Biological

US Biological

Boster

Thermo Fisher

VEGF Antibody Segment by Type

Rabbit

Mouse

Goat

Others

VEGF Antibody Segment by Application

Laboratory

Hospital

Others

VEGF Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global VEGF Antibody status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions VEGF Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify VEGF Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze VEGF Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the VEGF Antibody market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global VEGF Antibody industry.

Chapter 3: Detailed analysis of VEGF Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of VEGF Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of VEGF Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. VEGF Antibody Industry Trends Table 2. VEGF Antibody Industry Drivers Table 3. VEGF Antibody Industry Opportunities and Challenges Table 4. VEGF Antibody Industry Restraints Table 5. Global VEGF Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global VEGF Antibody Revenue Share by Company (2021-2026) Table 7. Global VEGF Antibody Sales Volume by Company (Kg) & (2021-2026) Table 8. Global VEGF Antibody Sales Volume Share by Company (2021-2026) Table 9. Global VEGF Antibody Average Price (US$/g) of Company (2021-2026) Table 10. Global VEGF Antibody Company Ranking, (2024-2026) & (USD Million) Table 11. Global VEGF Antibody Key Company Manufacturing Base & Headquarters Table 12. Global VEGF Antibody Company, Product Type & Application Table 13. Global VEGF Antibody Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global VEGF Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rabbit Table 18. Significant Companies of Mouse Table 19. Significant Companies of Goat Table 20. Significant Companies of Others Table 21. Global VEGF Antibody Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 22. Global VEGF Antibody Sales Volume by Type (2021-2026) & (Kg) Table 23. Global VEGF Antibody Sales Volume by Type (2027-2032) & (Kg) Table 24. Global VEGF Antibody Sales Volume Share by Type (2021-2026) Table 25. Global VEGF Antibody Sales Volume Share by Type (2027-2032) Table 26. Global VEGF Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global VEGF Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global VEGF Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global VEGF Antibody Sales Value Share by Type (2021-2026) Table 30. Global VEGF Antibody Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Laboratory Table 32. Significant Companies of Hospital Table 33. Significant Companies of Others Table 34. Global VEGF Antibody Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 35. Global VEGF Antibody Sales Volume by Application (2021-2026) & (Kg) Table 36. Global VEGF Antibody Sales Volume by Application (2027-2032) & (Kg) Table 37. Global VEGF Antibody Sales Volume Share by Application (2021-2026) Table 38. Global VEGF Antibody Sales Volume Share by Application (2027-2032) Table 39. Global VEGF Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global VEGF Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global VEGF Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global VEGF Antibody Sales Value Share by Application (2021-2026) Table 43. Global VEGF Antibody Sales Value Share by Application (2027-2032) Table 44. Global VEGF Antibody Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 45. Global VEGF Antibody Sales by Region (2021-2026) & (Kg) Table 46. Global VEGF Antibody Sales Market Share by Region (2021-2026) Table 47. Global VEGF Antibody Sales by Region (2027-2032) & (Kg) Table 48. Global VEGF Antibody Sales Market Share by Region (2027-2032) Table 49. Global VEGF Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global VEGF Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global VEGF Antibody Sales Value Share by Region (2021-2026) Table 52. Global VEGF Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global VEGF Antibody Sales Value Share by Region (2027-2032) Table 54. Global VEGF Antibody Market Average Price (US$/g) by Region (2021-2026) Table 55. Global VEGF Antibody Market Average Price (US$/g) by Region (2027-2032) Table 56. Global VEGF Antibody Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 57. Global VEGF Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global VEGF Antibody Sales by Country (2021-2026) & (Kg) Table 59. Global VEGF Antibody Sales Market Share by Country (2021-2026) Table 60. Global VEGF Antibody Sales by Country (2027-2032) & (Kg) Table 61. Global VEGF Antibody Sales Market Share by Country (2027-2032) Table 62. Global VEGF Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global VEGF Antibody Sales Value Market Share by Country (2021-2026) Table 64. Global VEGF Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global VEGF Antibody Sales Value Market Share by Country (2027-2032) Table 66. Abcam Company Information Table 67. Abcam Business Overview Table 68. Abcam VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 69. Abcam VEGF Antibody Product Portfolio Table 70. Abcam Recent Development Table 71. Abnova Company Information Table 72. Abnova Business Overview Table 73. Abnova VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 74. Abnova VEGF Antibody Product Portfolio Table 75. Abnova Recent Development Table 76. Absolute Antibody Company Information Table 77. Absolute Antibody Business Overview Table 78. Absolute Antibody VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 79. Absolute Antibody VEGF Antibody Product Portfolio Table 80. Absolute Antibody Recent Development Table 81. Agrisera Company Information Table 82. Agrisera Business Overview Table 83. Agrisera VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 84. Agrisera VEGF Antibody Product Portfolio Table 85. Agrisera Recent Development Table 86. BioLegend Company Information Table 87. BioLegend Business Overview Table 88. BioLegend VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 89. BioLegend VEGF Antibody Product Portfolio Table 90. BioLegend Recent Development Table 91. Bio-Rad Company Information Table 92. Bio-Rad Business Overview Table 93. Bio-Rad VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 94. Bio-Rad VEGF Antibody Product Portfolio Table 95. Bio-Rad Recent Development Table 96. Bon Opus Biosciences Company Information Table 97. Bon Opus Biosciences Business Overview Table 98. Bon Opus Biosciences VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 99. Bon Opus Biosciences VEGF Antibody Product Portfolio Table 100. Bon Opus Biosciences Recent Development Table 101. Creative Biomart Company Information Table 102. Creative Biomart Business Overview Table 103. Creative Biomart VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 104. Creative Biomart VEGF Antibody Product Portfolio Table 105. Creative Biomart Recent Development Table 106. Enzo Life Sciences Company Information Table 107. Enzo Life Sciences Business Overview Table 108. Enzo Life Sciences VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 109. Enzo Life Sciences VEGF Antibody Product Portfolio Table 110. Enzo Life Sciences Recent Development Table 111. ImmunoStar Company Information Table 112. ImmunoStar Business Overview Table 113. ImmunoStar VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 114. ImmunoStar VEGF Antibody Product Portfolio Table 115. ImmunoStar Recent Development Table 116. LifeSpan Biosciences Company Information Table 117. LifeSpan Biosciences Business Overview Table 118. LifeSpan Biosciences VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 119. LifeSpan Biosciences VEGF Antibody Product Portfolio Table 120. LifeSpan Biosciences Recent Development Table 121. MilliporeSigma Company Information Table 122. MilliporeSigma Business Overview Table 123. MilliporeSigma VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 124. MilliporeSigma VEGF Antibody Product Portfolio Table 125. MilliporeSigma Recent Development Table 126. Novus Biologicals Company Information Table 127. Novus Biologicals Business Overview Table 128. Novus Biologicals VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 129. Novus Biologicals VEGF Antibody Product Portfolio Table 130. Novus Biologicals Recent Development Table 131. OriGene Company Information Table 132. OriGene Business Overview Table 133. OriGene VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 134. OriGene VEGF Antibody Product Portfolio Table 135. OriGene Recent Development Table 136. ProMab Company Information Table 137. ProMab Business Overview Table 138. ProMab VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 139. ProMab VEGF Antibody Product Portfolio Table 140. ProMab Recent Development Table 141. R&D Systems Company Information Table 142. R&D Systems Business Overview Table 143. R&D Systems VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 144. R&D Systems VEGF Antibody Product Portfolio Table 145. R&D Systems Recent Development Table 146. Rockland Immunochemicals Company Information Table 147. Rockland Immunochemicals Business Overview Table 148. Rockland Immunochemicals VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 149. Rockland Immunochemicals VEGF Antibody Product Portfolio Table 150. Rockland Immunochemicals Recent Development Table 151. Santa Cruz Biotechnology Company Information Table 152. Santa Cruz Biotechnology Business Overview Table 153. Santa Cruz Biotechnology VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 154. Santa Cruz Biotechnology VEGF Antibody Product Portfolio Table 155. Santa Cruz Biotechnology Recent Development Table 156. Sino Biological Company Information Table 157. Sino Biological Business Overview Table 158. Sino Biological VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 159. Sino Biological VEGF Antibody Product Portfolio Table 160. Sino Biological Recent Development Table 161. US Biological Company Information Table 162. US Biological Business Overview Table 163. US Biological VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 164. US Biological VEGF Antibody Product Portfolio Table 165. US Biological Recent Development Table 166. Boster Company Information Table 167. Boster Business Overview Table 168. Boster VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 169. Boster VEGF Antibody Product Portfolio Table 170. Boster Recent Development Table 171. Thermo Fisher Company Information Table 172. Thermo Fisher Business Overview Table 173. Thermo Fisher VEGF Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 174. Thermo Fisher VEGF Antibody Product Portfolio Table 175. Thermo Fisher Recent Development Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. VEGF Antibody Distributors List Table 179. VEGF Antibody Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. VEGF Antibody Product Image Figure 2. Global VEGF Antibody Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGF Antibody Sales Value (2021-2032) & (US$ Million) Figure 4. Global VEGF Antibody Sales (2021-2032) & (Kg) Figure 5. Global VEGF Antibody Sales Average Price (US$/g) & (2021-2032) Figure 6. Global VEGF Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rabbit Image Figure 10. Mouse Image Figure 11. Goat Image Figure 12. Others Image Figure 13. Global VEGF Antibody Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 14. Global VEGF Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global VEGF Antibody Sales Volume Share by Type (2021-2032) Figure 16. Global VEGF Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global VEGF Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global VEGF Antibody Sales Value Share by Type (2021-2032) Figure 19. Laboratory Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global VEGF Antibody Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 23. Global VEGF Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global VEGF Antibody Sales Volume Share by Application (2021-2032) Figure 25. Global VEGF Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global VEGF Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global VEGF Antibody Sales Value Share by Application (2021-2032) Figure 28. Global VEGF Antibody Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 29. Global VEGF Antibody Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global VEGF Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global VEGF Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America VEGF Antibody Sales Value (2021-2032) & (US$ Million) Figure 33. North America VEGF Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe VEGF Antibody Sales Value (2021-2032) & (US$ Million) Figure 35. Europe VEGF Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific VEGF Antibody Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific VEGF Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America VEGF Antibody Sales Value (2021-2032) & (US$ Million) Figure 39. South America VEGF Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa VEGF Antibody Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa VEGF Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt VEGF Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt VEGF Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt VEGF Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. VEGF Antibody Value Chain Figure 127. Manufacturing Cost Structure Figure 128. VEGF Antibody Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Rabbit
  • Mouse
  • Goat
  • Others
Applications
  • Laboratory
  • Hospital
  • Others
Companies covered
  • Abcam
  • Abnova
  • Absolute Antibody
  • Agrisera
  • BioLegend
  • Bio-Rad
  • Bon Opus Biosciences
  • Creative Biomart
  • Enzo Life Sciences
  • ImmunoStar
  • LifeSpan Biosciences
  • MilliporeSigma
  • Novus Biologicals
  • OriGene
  • ProMab
  • R&D Systems
  • Rockland Immunochemicals
  • Santa Cruz Biotechnology
  • Sino Biological
  • US Biological
  • Boster
  • Thermo Fisher

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global VEGF Antibody Sales Value (2021-2032)
  4. 1.2.2 Global VEGF Antibody Sales Volume (2021-2032)
  5. 1.2.3 Global VEGF Antibody Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 VEGF Antibody Market Dynamics
  1. 2.1 VEGF Antibody Industry Trends
  2. 2.2 VEGF Antibody Industry Drivers
  3. 2.3 VEGF Antibody Industry Opportunities and Challenges
  4. 2.4 VEGF Antibody Industry Restraints
3 VEGF Antibody Market by Company
  1. 3.1 Global VEGF Antibody Company Revenue Ranking in 2025
  2. 3.2 Global VEGF Antibody Revenue by Company (2021-2026)
  3. 3.3 Global VEGF Antibody Sales Volume by Company (2021-2026)
  4. 3.4 Global VEGF Antibody Average Price by Company (2021-2026)
  5. 3.5 Global VEGF Antibody Company Ranking (2024-2026)
  6. 3.6 Global VEGF Antibody Company Manufacturing Base and Headquarters
  7. 3.7 Global VEGF Antibody Company Product Type and Application
  8. 3.8 Global VEGF Antibody Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global VEGF Antibody Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 VEGF Antibody Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 VEGF Antibody Market by Type
  1. 4.1 VEGF Antibody Type Introduction
  2. 4.1.1 Rabbit
  3. 4.1.2 Mouse
  4. 4.1.3 Goat
  5. 4.1.4 Others
  6. 4.2 Global VEGF Antibody Sales Volume by Type
  7. 4.2.1 Global VEGF Antibody Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global VEGF Antibody Sales Volume by Type (2021-2032)
  9. 4.2.3 Global VEGF Antibody Sales Volume Share by Type (2021-2032)
  10. 4.3 Global VEGF Antibody Sales Value by Type
  11. 4.3.1 Global VEGF Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global VEGF Antibody Sales Value by Type (2021-2032)
  13. 4.3.3 Global VEGF Antibody Sales Value Share by Type (2021-2032)
5 VEGF Antibody Market by Application
  1. 5.1 VEGF Antibody Application Introduction
  2. 5.1.1 Laboratory
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global VEGF Antibody Sales Volume by Application
  6. 5.2.1 Global VEGF Antibody Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VEGF Antibody Sales Volume by Application (2021-2032)
  8. 5.2.3 Global VEGF Antibody Sales Volume Share by Application (2021-2032)
  9. 5.3 Global VEGF Antibody Sales Value by Application
  10. 5.3.1 Global VEGF Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global VEGF Antibody Sales Value by Application (2021-2032)
  12. 5.3.3 Global VEGF Antibody Sales Value Share by Application (2021-2032)
6 VEGF Antibody Regional Sales and Value Analysis
  1. 6.1 Global VEGF Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VEGF Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global VEGF Antibody Sales by Region: 2021-2026
  4. 6.2.2 Global VEGF Antibody Sales by Region (2027-2032)
  5. 6.3 Global VEGF Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global VEGF Antibody Sales Value by Region (2021-2032)
  7. 6.4.1 Global VEGF Antibody Sales Value by Region: 2021-2026
  8. 6.4.2 Global VEGF Antibody Sales Value by Region (2027-2032)
  9. 6.5 Global VEGF Antibody Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America VEGF Antibody Sales Value (2021-2032)
  12. 6.6.2 North America VEGF Antibody Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe VEGF Antibody Sales Value (2021-2032)
  15. 6.7.2 Europe VEGF Antibody Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific VEGF Antibody Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific VEGF Antibody Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America VEGF Antibody Sales Value (2021-2032)
  21. 6.9.2 South America VEGF Antibody Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa VEGF Antibody Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa VEGF Antibody Sales Value Share by Country, 2025 VS 2032
7 VEGF Antibody Country-level Sales and Value Analysis
  1. 7.1 Global VEGF Antibody Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global VEGF Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global VEGF Antibody Sales by Country (2021-2032)
  4. 7.3.1 Global VEGF Antibody Sales by Country (2021-2026)
  5. 7.3.2 Global VEGF Antibody Sales by Country (2027-2032)
  6. 7.4 Global VEGF Antibody Sales Value by Country (2021-2032)
  7. 7.4.1 Global VEGF Antibody Sales Value by Country (2021-2026)
  8. 7.4.2 Global VEGF Antibody Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA VEGF Antibody Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada VEGF Antibody Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico VEGF Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany VEGF Antibody Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France VEGF Antibody Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. VEGF Antibody Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy VEGF Antibody Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain VEGF Antibody Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia VEGF Antibody Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands VEGF Antibody Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries VEGF Antibody Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China VEGF Antibody Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan VEGF Antibody Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea VEGF Antibody Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India VEGF Antibody Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia VEGF Antibody Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia VEGF Antibody Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil VEGF Antibody Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina VEGF Antibody Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile VEGF Antibody Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia VEGF Antibody Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru VEGF Antibody Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia VEGF Antibody Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel VEGF Antibody Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE VEGF Antibody Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey VEGF Antibody Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran VEGF Antibody Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran VEGF Antibody Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt VEGF Antibody Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt VEGF Antibody Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt VEGF Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abcam
  2. 8.1.1 Abcam Company Information
  3. 8.1.2 Abcam Business Overview
  4. 8.1.3 Abcam VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abcam VEGF Antibody Product Portfolio
  6. 8.1.5 Abcam Recent Developments
  7. 8.2 Abnova
  8. 8.2.1 Abnova Company Information
  9. 8.2.2 Abnova Business Overview
  10. 8.2.3 Abnova VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Abnova VEGF Antibody Product Portfolio
  12. 8.2.5 Abnova Recent Developments
  13. 8.3 Absolute Antibody
  14. 8.3.1 Absolute Antibody Company Information
  15. 8.3.2 Absolute Antibody Business Overview
  16. 8.3.3 Absolute Antibody VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Absolute Antibody VEGF Antibody Product Portfolio
  18. 8.3.5 Absolute Antibody Recent Developments
  19. 8.4 Agrisera
  20. 8.4.1 Agrisera Company Information
  21. 8.4.2 Agrisera Business Overview
  22. 8.4.3 Agrisera VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Agrisera VEGF Antibody Product Portfolio
  24. 8.4.5 Agrisera Recent Developments
  25. 8.5 BioLegend
  26. 8.5.1 BioLegend Company Information
  27. 8.5.2 BioLegend Business Overview
  28. 8.5.3 BioLegend VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BioLegend VEGF Antibody Product Portfolio
  30. 8.5.5 BioLegend Recent Developments
  31. 8.6 Bio-Rad
  32. 8.6.1 Bio-Rad Company Information
  33. 8.6.2 Bio-Rad Business Overview
  34. 8.6.3 Bio-Rad VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bio-Rad VEGF Antibody Product Portfolio
  36. 8.6.5 Bio-Rad Recent Developments
  37. 8.7 Bon Opus Biosciences
  38. 8.7.1 Bon Opus Biosciences Company Information
  39. 8.7.2 Bon Opus Biosciences Business Overview
  40. 8.7.3 Bon Opus Biosciences VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bon Opus Biosciences VEGF Antibody Product Portfolio
  42. 8.7.5 Bon Opus Biosciences Recent Developments
  43. 8.8 Creative Biomart
  44. 8.8.1 Creative Biomart Company Information
  45. 8.8.2 Creative Biomart Business Overview
  46. 8.8.3 Creative Biomart VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Creative Biomart VEGF Antibody Product Portfolio
  48. 8.8.5 Creative Biomart Recent Developments
  49. 8.9 Enzo Life Sciences
  50. 8.9.1 Enzo Life Sciences Company Information
  51. 8.9.2 Enzo Life Sciences Business Overview
  52. 8.9.3 Enzo Life Sciences VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Enzo Life Sciences VEGF Antibody Product Portfolio
  54. 8.9.5 Enzo Life Sciences Recent Developments
  55. 8.10 ImmunoStar
  56. 8.10.1 ImmunoStar Company Information
  57. 8.10.2 ImmunoStar Business Overview
  58. 8.10.3 ImmunoStar VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 ImmunoStar VEGF Antibody Product Portfolio
  60. 8.10.5 ImmunoStar Recent Developments
  61. 8.11 LifeSpan Biosciences
  62. 8.11.1 LifeSpan Biosciences Company Information
  63. 8.11.2 LifeSpan Biosciences Business Overview
  64. 8.11.3 LifeSpan Biosciences VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 LifeSpan Biosciences VEGF Antibody Product Portfolio
  66. 8.11.5 LifeSpan Biosciences Recent Developments
  67. 8.12 MilliporeSigma
  68. 8.12.1 MilliporeSigma Company Information
  69. 8.12.2 MilliporeSigma Business Overview
  70. 8.12.3 MilliporeSigma VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 MilliporeSigma VEGF Antibody Product Portfolio
  72. 8.12.5 MilliporeSigma Recent Developments
  73. 8.13 Novus Biologicals
  74. 8.13.1 Novus Biologicals Company Information
  75. 8.13.2 Novus Biologicals Business Overview
  76. 8.13.3 Novus Biologicals VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Novus Biologicals VEGF Antibody Product Portfolio
  78. 8.13.5 Novus Biologicals Recent Developments
  79. 8.14 OriGene
  80. 8.14.1 OriGene Company Information
  81. 8.14.2 OriGene Business Overview
  82. 8.14.3 OriGene VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 OriGene VEGF Antibody Product Portfolio
  84. 8.14.5 OriGene Recent Developments
  85. 8.15 ProMab
  86. 8.15.1 ProMab Company Information
  87. 8.15.2 ProMab Business Overview
  88. 8.15.3 ProMab VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 ProMab VEGF Antibody Product Portfolio
  90. 8.15.5 ProMab Recent Developments
  91. 8.16 R&D Systems
  92. 8.16.1 R&D Systems Company Information
  93. 8.16.2 R&D Systems Business Overview
  94. 8.16.3 R&D Systems VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 R&D Systems VEGF Antibody Product Portfolio
  96. 8.16.5 R&D Systems Recent Developments
  97. 8.17 Rockland Immunochemicals
  98. 8.17.1 Rockland Immunochemicals Company Information
  99. 8.17.2 Rockland Immunochemicals Business Overview
  100. 8.17.3 Rockland Immunochemicals VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Rockland Immunochemicals VEGF Antibody Product Portfolio
  102. 8.17.5 Rockland Immunochemicals Recent Developments
  103. 8.18 Santa Cruz Biotechnology
  104. 8.18.1 Santa Cruz Biotechnology Company Information
  105. 8.18.2 Santa Cruz Biotechnology Business Overview
  106. 8.18.3 Santa Cruz Biotechnology VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Santa Cruz Biotechnology VEGF Antibody Product Portfolio
  108. 8.18.5 Santa Cruz Biotechnology Recent Developments
  109. 8.19 Sino Biological
  110. 8.19.1 Sino Biological Company Information
  111. 8.19.2 Sino Biological Business Overview
  112. 8.19.3 Sino Biological VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Sino Biological VEGF Antibody Product Portfolio
  114. 8.19.5 Sino Biological Recent Developments
  115. 8.20 US Biological
  116. 8.20.1 US Biological Company Information
  117. 8.20.2 US Biological Business Overview
  118. 8.20.3 US Biological VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 US Biological VEGF Antibody Product Portfolio
  120. 8.20.5 US Biological Recent Developments
  121. 8.21 Boster
  122. 8.21.1 Boster Company Information
  123. 8.21.2 Boster Business Overview
  124. 8.21.3 Boster VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Boster VEGF Antibody Product Portfolio
  126. 8.21.5 Boster Recent Developments
  127. 8.22 Thermo Fisher
  128. 8.22.1 Thermo Fisher Company Information
  129. 8.22.2 Thermo Fisher Business Overview
  130. 8.22.3 Thermo Fisher VEGF Antibody Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Thermo Fisher VEGF Antibody Product Portfolio
  132. 8.22.5 Thermo Fisher Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 VEGF Antibody Value Chain Analysis
  2. 9.1.1 VEGF Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 VEGF Antibody Sales Mode & Process
  6. 9.2 VEGF Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 VEGF Antibody Distributors
  9. 9.2.3 VEGF Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst